Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy

被引：45

作者：

Di Silverio, Franco ^{[1
]}

Sciarra, Alessandro ^{[1
]}

Parente, Ulderico ^{[1
]}

Andrea, Alfarone ^{[1
]}

Von Heland, Magnus ^{[1
]}

Panebianco, Valeria ^{[2
]}

Passariello, Roberto ^{[2
]}

机构：

[1] Univ Rome, Dept Urol, Rome, Italy

[2] Univ Rome, Dept Pathol, Rome, Italy

来源：

UROLOGIA INTERNATIONALIS | 2008年 / 80卷 / 04期

关键词：

renal cancer; thrombus; sunitinib;

D O I：

10.1159/000132708

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A 71-year- old man with advanced left renal cell carcinoma ( lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy. After sorafenib treatment and before surgery a new CT scan confirmed the presence of a 9.0 cm in diameter solid mass in the left kidney but a reduction in thrombus extension, limited to the left renal vein. At histological examination after radical nephrectomy, over 90% of the renal mass was substituted by necrotic tissue. Copyright (c) 2008 S. Karger AG, Basel.

引用

页码：451 / 453

页数：3

共 5 条

[1]

Escudier B, 2005, EJC SUPPL, V3, P226

[2] Vascular endothelial growth factor as a target for anticancer therapy [J].